Kailera Therapeutics (NASDAQ:KLRA) Shares Up 9.8% – Here’s What Happened

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price rose 9.8% on Wednesday . The stock traded as high as $20.37 and last traded at $20.36. Approximately 219,072 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 610,344 shares. The stock had previously closed at $18.55.

Analyst Ratings Changes

KLRA has been the topic of several analyst reports. Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price objective on the stock. Zacks Research raised Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. TD Cowen initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective on the stock. Evercore initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating on the stock. Finally, William Blair initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Up 5.3%

The business has a 50 day moving average of $22.01.

Insider Buying and Selling at Kailera Therapeutics

In other Kailera Therapeutics news, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the purchase, the director owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This trade represents a 47.03% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Adam Koppel purchased 1,562,500 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were acquired at an average price of $16.00 per share, with a total value of $25,000,000.00. Following the purchase, the director directly owned 22,583,268 shares in the company, valued at $361,332,288. This represents a 7.43% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.